240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
News, Material Contracts
ORIC Pharmaceuticals Amends 2020 Equity Incentive Plan
Reports First Quarter 2026 Financial Results and Operational Updates
Annual Report to Security Holders
Investor Presentation
ORIC Pharmaceuticals Enters $200 Million Sales Agreement with Jefferies
Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload